title: Cerebral microbleeds as a biomarker in Alzheimer's disease? A review in the field.
abstract: Cerebral microbleeds (CMBs) are a marker of small vessel disease, increasingly recognized as being of importance in the Alzheimer's disease (AD) process. CMBs influence in AD, and its longitudinal impact on disease progression is however still unknown. CMBs show several associations with AD across studies, are associated with decreased cerebrospinal fluid amyloid levels and are related with the ApoE ϵ4 allele, as well as other imaging manifestations typical for small vessel disease. CMBs, in addition to other markers of small vessel disease, are important to discover further in order to discern possible AD phenotypes.
authors.affiliation: Department of Clinical Science, Intervention & Technology, Division of Medical Imaging & Technology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Sara
authors.initials: S
authors.lastname: Shams
authors.affiliation: Department of Neurobiology, Care Sciences & Society, Karolinska Institutet, Stockholm, Sweden. Division of Clinical Geriatrics, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Lars-Olof
authors.initials: LO
authors.lastname: Wahlund
mesh_terms: D000544:Alzheimer Disease / Q000150:complications*; D001057:Apolipoproteins E / Q000235:genetics; D015415:Biomarkers; D002543:Cerebral Hemorrhage / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics; D006801:Humans; D015995:Prevalence; D012307:Risk Factors
chemical_list: D001057:Apolipoproteins E; D015415:Biomarkers
keywords: Alzheimer's disease; MRI; amyloid; apolipoprotein ϵ allele; biomarkers; cerebral microbleeds; cerebrospinal fluid; small vessel disease